← Companies|Glenmark Pharma
GL

Glenmark Pharma

GLENMARK.NS·NSEMumbai INFounded 197715,000 employees
Mid CappharmaPublicDermatologyRespiratory
Platform: Innov Derm
Market Cap
$3B
All Drugs
3
Clinical Trials
6
Failed / Terminated
3
FDA Approved
0
Stock Price & Catalysts (GLENMARK.NS)
Loading GLENMARK.NS stock data...
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
RimanesiranGLE-4024Phase 2/31mAbSGLT2Cl18.2CholangiocarcinomaMyelofibrosis
PemiglumideGLE-3455NDA/BLA2ADCAuroraABiTEMM
ZoriosocimabGLE-2892Phase 33DegraderMETHPK1iMCCNSCLC
SEC Filings & Financial Documents
SEC filings are not available for NSE-listed companies.
Glenmark Pharma trades on NSE (IN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (7)
2025-11-02
Pemiglumide Ph1 Dose Esc
MM
Past
2026-07-01
Zoriosocimab Ph3 Readout
NMOSD
Ph3 Readout
2026-10-17
Zoriosocimab EMA Filing
NSCLC
EMA Filing
2026-10-23
Pemiglumide Ph3 Readout
MM
Ph3 Readout
2027-09-01
Pemiglumide Ph3 Readout
MM
Ph3 Readout
2028-05-03
Rimanesiran Ph3 Readout
Myelofibrosis
Ph3 Readout
2030-02-02
Zoriosocimab Ph3 Readout
MCC
Ph3 Readout